Clinical trial for Central Centrifugal Cicatricial Alopecia (CCCA)
Official title Tirzepatide for Treatment of CCCA
ClinicalTrials.gov ID: NCT07734870
What this study is testing
What is Tirzepatide?
Tirzepatide is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for central centrifugal cicatricial alopecia (ccca).
Also referred to as Mounjaro, Zepbound.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults. The main questions it aims to answer are: Does tirzepatide improve the symptoms and signs of active CCCA?
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age 18 to 80 years.
- Clinical and/or biopsy-confirmed diagnosis of central centrifugal cicatricial alopecia (CCCA).
- Active CCCA, defined as a C-CAT disease activity score greater than 1.
- No treatment for CCCA during the 6 weeks before enrollment.
- Able and willing to complete the study and follow all study procedures.
You likely can't join if
- Currently taking an oral or systemic blood glucose-lowering medication.
- Currently taking another medication for weight loss.
- Hemoglobin A1C below 5.4%.
- Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) score below 2.
- Body mass index below 19 kg/m².
- Pregnant, breastfeeding, or planning a pregnancy.
See the full eligibility criteria
- Age 18 to 80 years.
- Clinical and/or biopsy-confirmed diagnosis of central centrifugal cicatricial alopecia (CCCA).
- Active CCCA, defined as a C-CAT disease activity score greater than 1.
- No treatment for CCCA during the 6 weeks before enrollment.
- Able and willing to complete the study and follow all study procedures.
- Managed by a Johns Hopkins dermatologist throughout the study.
- Currently taking an oral or systemic blood glucose-lowering medication.
- Currently taking another medication for weight loss.
- Hemoglobin A1C below 5.4%.
- Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) score below 2.
- Body mass index below 19 kg/m².
- Pregnant, breastfeeding, or planning a pregnancy.
- Personal or family history of medullary thyroid cancer.
- Personal or family history of multiple endocrine neoplasia type 2.
- History of chronic kidney disease.
- History of pancreatitis.
- History of diabetic retinopathy.
- Severe gastrointestinal disease.
- Recent or planned major surgery.
- Type 1 diabetes.
- Any other contraindication to tirzepatide.
- History of keloids or hypertrophic scarring.
- History of poor wound healing.
- History of a blood-clotting disorder.
- Allergy to lidocaine or epinephrine.
- Known sensitivity to local numbing medication.
- Any significant medical condition that the investigator believes would make participation unsafe or prevent completion of the study.
The study team makes the final eligibility decision.
Where it's taking place
- Baltimore, Maryland, United States
- Columbia, Maryland, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Baltimore, Maryland, United States; Columbia, Maryland, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.